Abstract
Introduction
WHIM syndrome is a rare congenital immunodeficiency disorder, with approximately 40 cases reported to date worldwide [1] . The word 'WHIM' is an acronym for the main clinical manifestations: warts, hypogammaglobulinemia, recurrent bacterial infections and myelokathexis (severe, non-cyclical neutropenia with increased retention of mature myeloid cells in bone marrow) [2, 3] . The cause of almost all cases of WHIM syndrome is autosomal dominant inheritance of mutations in the gene encoding the chemokine receptor CXCR4, which truncate 10-19 amino acids from the C-terminus [4] . Most common is the 1000C→T nonsense mutation, which truncates 19 amino acids, creating a protein which we will refer to as CXCR4 R334X [1] .
Mechanisms by which WHIM mutations alter CXCR4 function and lead to WHIM phenotypes have not yet been fully delineated. Hernandez et al. was first to report that a WHIM variant of CXCR4, specifically CXCR4

R334X
, has modestly increased signalling capacity in response to the endogenous CXCR4 ligand CXCL12 (also known as stromal cell-derived factor-1 or SDF-1), as revealed by an intracellular calcium flux assay [4] . Using an F-actin polymerization assay, the mutant receptor was later reported to be less readily desensitized than wild-type receptor [5] . Increased signalling has been attributed in part to reduced mutant receptor down-regulation from the cell surface after activation [6] . Since CXCR4 normally promotes homing of haematopoietic progenitor cells (HPC) [7] . Patients with WHIM syndrome have deficiencies in multiple other leucocyte subsets in blood perhaps due to related redistribution mechanisms, and in the case of B lymphocytopenia this may help explain the hypogammaglobulinemia phenotype [1] . CXCR4 knockout mice have defective B lymphopoiesis and myelopoiesis, providing independent loss-of-function evidence that CXCR4 normally regulates phagocyte and B lymphocyte development [8] [9] [10] [11] . [12] . A limitation of studies using primary cells from patients is that the stoichiometry of the putative mutant and wildtype receptors cannot be determined. In addition, CXCR4 signalling has also been reported to promote anti-apoptotic and proliferative effects in various cell types and systems, which could contribute to WHIM phenotypes [13] . 
Despite these advances, there is still no clear understanding of the precise biochemical mechanism by which WHIM mutations cause WHIM phenotypes. The reported increase in signalling is modest, and the specific pathways tested have not been linked directly to the observed phenotypes. In addition, it is not clear that the properties of the WHIM receptor tested in transfectants are representative of function in primary cells from patients. On the contrary, one group has reported that leucocytes from WHIM patients had normal CXCR4 calcium signalling in T cells cultured for 3 weeks
Materials and methods
Construction of stably transfected cell lines
The eukaryotic expression vector pcDNA3.1 (-) 
Measurement of pERK1/2 and pAkt
Analysis of extracellular signal-related kinase (ERK) and Akt activation upon CXCL12 treatment was performed with a previously described flow cytometry method [16, 17] (Fig. 5B) . ERK phosphorylation (Fig. 5D, F) and Akt activation (Fig. 5F) (Fig. 6A) (Fig. 6E ), but the majority of both normal and WHIM neutrophil chemotaxis to 30 nM CXCL12 could be blocked by 0.5 M AMD3100 (Fig. 6F) . (D-F) , the stimulus is 10 nM CXCL12. [24] [25] [26] . While effective in preventing recurrent bacterial infections, neither therapy appears to control warts, which can develop into potentially fatal squamous cell carcinoma in the oral cavity and genital region [27] . Some authors have also suggested that long-term treatment with G-CSF may result in increased risk of myeloid leukaemia or myelodysplasia [28, 29] 
. This protocol revealed that AMD3100 could effectively block the signal mediated by mutant and wild-type receptors in both cell types, with equivalent potency and efficacy. In particular, near complete inhibition required ~10 M of AMD3100 for both receptor forms in both cell types, and the IC50 (concentration at which half of the maximal signal was blocked) was ~1 M for all four transfectants (Fig. 6B). Consistent with this, AMD3100 was also able to inhibit calcium flux induced by 10 nM CXCL12 in PBMCs from our WHIM patient with the CXCR4 R334X mutation with similar potency and efficacy as for PBMCs from healthy controls (Fig. 6C). This result was also confirmed in two other paediatric patients with the same mutation (data not shown). Moreover, the active range was similar to that observed for CXCR4 WT and CXCR4 R334X expressed in CHO and K562 cells. AMD3100 was also potent and effective at suppressing the CXCL12-induced phosphorylation of ERK by both receptor forms in K562 cells (Fig. 6D) and in CHO cells and AMD3100 could block the CXCL12-induced Akt phosphorylation by both receptor subtypes in K562 cells with approximately half the signal being blocked at 1 M and near complete blockade at 10 M (data not shown). Neutrophil chemotaxis to CXCL12 was enhanced in our patient
